Vir Biotechnology, Inc. VIR Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vir Biotechnology, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vir Biotechnology, Inc.'s business segments — net loss?
- Vir Biotechnology, Inc. (VIR) reported business segments — net loss of -$125.7M in Q1 2026.
- How has Vir Biotechnology, Inc.'s business segments — net loss changed year-over-year?
- Vir Biotechnology, Inc.'s business segments — net loss decreased by 3.9% year-over-year, from -$120.97M to -$125.7M.
- What is the long-term trend for Vir Biotechnology, Inc.'s business segments — net loss?
- Over 3 years (2022 to 2025), Vir Biotechnology, Inc.'s business segments — net loss has grown at a -5.3% compound annual growth rate (CAGR), from $515.84M to -$437.99M.
- What does business segments — net loss mean?
- Indicates the bottom-line financial performance of the segment after accounting for all revenues and operating expenses. A net loss reflects the current stage of the segment's lifecycle, typically indicating high investment in R&D relative to revenue generation.